Zeidan Discusses Feasibility of Long-Term Ziftomenib Use in AML

In an interview with Targeted Oncology, Amer Zeidan, MBBS, MHS, chief, division of hematologic malignancies at Yale Cancer Center and professor of medicine at Yale School of Medicine discusses the long-term feasibility of administering ziftomenib (Komzifti) in patients with acute myeloid leukemia (AML), including insights from the phase 1b/2 KOMET-007 trial (NCT05735184) presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden.

Watch part 1 and part 2 of Dr Zeidan’s interview.

As menin inhibitors move into earlier lines of therapy and maintenance strategies are explored, long-term tolerability has become an important consideration for both physicians and patients. Drawing on his experience treating patients enrolled in KOMET-007, Zeidan explains why ziftomenib has proven to be a practical therapy to administer over extended periods.

According to Zeidan, most adverse effects observed during combination treatment are driven by the chemotherapy backbone rather than ziftomenib itself. Rates of treatment-associated differentiation syndrome and QTc prolongation have remained low, and the agent's once-daily oral administration and limited drug-drug interactions have helped simplify treatment management in clinical practice.

Zeidan also reviews the adverse effects most commonly associated with ziftomenib, including occasional low-grade pruritus and mild gastrointestinal symptoms, which he notes are generally manageable and well tolerated. Patients receiving ziftomenib as maintenance monotherapy have reported minimal treatment-related toxicities, supporting the potential for prolonged administration following induction and consolidation therapy.